Title: 2017 ACVIM Forum Research Abstract Program Document date: 2017_6_15
ID: ri2w5iby_175
Snippet: HER2/neu is an epidermal growth factor receptor tyrosine kinase that is expressed in human cancers of the prostate, breast, ovary, stomach, and colon. HER2/neu expression is reported in up to 60% of human pediatric osteosarcomas, where increased expression correlates with aggressive biologic behavior and an increased risk of metastasis. Contrary to the membranous expression seen in carcinomas, HER2/neu expression in OSA is principally cytoplasmic.....
Document: HER2/neu is an epidermal growth factor receptor tyrosine kinase that is expressed in human cancers of the prostate, breast, ovary, stomach, and colon. HER2/neu expression is reported in up to 60% of human pediatric osteosarcomas, where increased expression correlates with aggressive biologic behavior and an increased risk of metastasis. Contrary to the membranous expression seen in carcinomas, HER2/neu expression in OSA is principally cytoplasmic. In canine patients, one previous retrospective study reported HER2 expression in 4/10 primary tumor samples, with a suggestion that HER2 expression correlated with decreased survival. We therefore hypothesized that HER2 expression in canine OSA denotes a more aggressive disease phenotype.
Search related documents:
Co phrase search for related documents- aggressive disease phenotype and disease phenotype: 1, 2
- biologic behavior and growth factor: 1
- biologic behavior and tyrosine kinase: 1
- breast prostate and colon stomach: 1, 2
- breast prostate and growth factor: 1, 2, 3, 4, 5
- breast prostate and HER2 expression: 1
- breast prostate and human cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- breast prostate and increase expression: 1, 2
- breast prostate and increase risk: 1, 2
- breast prostate and retrospective study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- breast prostate and tyrosine kinase: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date